Pia Maarit Herbolsheimer MD
Assistant Professor, Medicine, Georgetown Univ Sch of Med
Join to view full profile
110 Irving St NwWashington, DC 20010
Phone+1 202-877-7000
Join Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 1 invite waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Pia Herbolsheimer, MD is an oncologist in Washington, District of Columbia. She is an Assistant Professor at Georgetown Univ Sch of Med.
Education & Training
MedStar Health Georgetown UniversityFellowship, Hematology and Medical Oncology, 2007 - 2010- MedStar Health Georgetown University/Georgetown HospitalResidency, Internal Medicine, 2004 - 2007
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification MEDSEEK Empower, SymphonyCare, LLC, 2013-2014, 2017
- CMS Meaningful Use Stage 2 Certification ARIA Oncology Information System (for Medical Oncology), Varian Medical Systems, 2013-2014, 2017
- CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2013-2014, 2017
Publications & Presentations
PubMed
- 40 citationsOlaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study.Matthew G Krebs, Jean-Pierre Delord, Thomas R Jeffry Evans, Maja De Jonge, Sang-We Kim
Lung Cancer. 2023-06-01 - 28 citationsLong-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compr...Katia E. Khoury, Filipa Lynce, Ana Barac, Xue Geng, Chau T. Dang
Breast Cancer Research and Treatment. 2021-01-05 - 364 citationsOlaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.Susan M. Domchek, Sophie Postel-Vinay, Seock-Ah Im, Yeon Hee Park, Jean Pierre Delord
The Lancet. Oncology. 2020-09-01